CONTRACT PHARMACAL today announced that the FDA has granted approval for its ANDA #219603, a milestone likely to boost the company's generic revenue streams as it prepares for the product's impending commercial launch. Market participants are expected to view this clearance as a sign of strong downstream manufacturing demand and potential earnings upside.